On November 9, 2023, Leon O. Moulder, Jr. informed Trevena (the Company") of his planned retirement from the Board of Directors of the company, effective as of December 31, 2023. In connection with his retirement, Mr. Moulder also resigned as Chairman of the Board, effective immediately. Mr. Moulder has confirmed to the company that his departure is not the result of any disagreement with the company on any matter relating to the Company's operations, policies or practices. In conjunction with Mr. Moulder's resignation as Chairman of the Board, the Board has appointed and approved Carrie Bourdow, the Company's President and Chief Executive Officer, as the new Chair of the Board, and Scott Braunstein, M.D. as the Lead Independent Director of the Board effective immediately.
Mr. Moulder has served on the Company's Board and as Chairman since 2013. The Company and the Board would like
to thank Mr. Moulder for his many contributions to the Company as it advanced through several important
milestones over the last 10 years," said Carrie Bourdow.
Dr. Braunstein has been a key member of the Company's Board since 2019. The Board believes that his experience
across roles in the financial sectors at Aisling Capital and J.P. Morgan, as well as his leadership positions
as the former Chief Operating Officer at Pacira BioSciences, Inc. and as the current CEO and Chairman of the
Board of Marinus Pharmaceuticals Inc. best position Dr. Braunstein to serve as the Lead Independent Director
of the Company.
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Companyâs pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).
TREVENA, INC. 
